Literature DB >> 9894470

The pathologic and clinical spectrum of anaplastic large cell lymphoma and correlation with ALK gene dysregulation.

M C Kinney1, M E Kadin.   

Abstract

Anaplastic large cell lymphoma (ALCL) is clinically and pathologically heterogeneous, leading to some difficulty in its diagnosis and acceptance as a specific entity. ALCL can be subdivided into different groups according to histologic features (pleomorphic, monomorphic, small cell predominant, Hodgkin's disease-related, and other less common variants), immunophenotype (T, null, B, and rarely B and T), and clinical features (systemic, primary cutaneous type, ALCL arising in HIV-positive patients, and ALCL occurring after another lymphoproliferative process, such as lymphomatoid papulosis, mycosis fungoides, and Hodgkin's disease. Cytogenetic studies and subsequent cloning of the translocation t(2;5) have shown a high degree of association with Ki-1-positive lymphoma but have revealed that this genetic abnormality is not specific for anaplastic morphologic features, is more common in the monomorphic and small cell variants, and is rare in primary cutaneous ALCL. It is likely that this t(2;5)-positive group is pathogenetically related. The purpose of this article is to review the pathologic and clinical spectrum of ALCL, including the borderline with Hodgkin's disease and lymphomatoid papulosis and to discuss the use of the t(2;5) in better defining a more specific molecular pathologic entity within this group of diseases with CD30 expression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9894470

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  5 in total

1.  An unusual case of posttransplant peritoneal primary effusion lymphoma with T-cell phenotype in a HIV-negative female, not associated with HHV-8.

Authors:  Ioannis Venizelos; Demetrio Tamiolakis; Maria Lambropoulou; Sylva Nikolaidou; Sophia Bolioti; Hlias Papadopoulos; Nikolas Papadopoulos
Journal:  Pathol Oncol Res       Date:  2005-09-29       Impact factor: 3.201

2.  A murine xenograft model for human CD30+ anaplastic large cell lymphoma. Successful growth inhibition with an anti-CD30 antibody (HeFi-1).

Authors:  W Pfeifer; E Levi; T Petrogiannis-Haliotis; L Lehmann; Z Wang; M E Kadin
Journal:  Am J Pathol       Date:  1999-10       Impact factor: 4.307

3.  Primary systemic anaplastic large cell lymphoma in a single Korean institution: clinical characteristics and treatment outcome.

Authors:  Sook Ryun Park; Ji Yeon Baek; Dong-Wan Kim; Seok-Ah Im; Tae-You Kim; Yung-Jue Bang; Noe Kyeong Kim; Yoon Kyung Jeon; Chul Woo Kim; Dae Seog Heo
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

Review 4.  Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.

Authors:  Thomas R Webb; Jake Slavish; Rani E George; A Thomas Look; Liquan Xue; Qin Jiang; Xiaoli Cui; Walter B Rentrop; Stephan W Morris
Journal:  Expert Rev Anticancer Ther       Date:  2009-03       Impact factor: 4.512

5.  [Anaplastic large cell lymphoma and keratoacanthoma].

Authors:  M Tronnier; H Merz
Journal:  Hautarzt       Date:  2004-02       Impact factor: 0.751

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.